Astellas' Vaprisol Receives Second Indication
This article was originally published in PharmAsia News
Executive Summary
FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2